US2021122821A1PendingUtilityA1
Neutralization of inhibitory pathways in lymphocytes
Est. expiryJan 21, 2036(~9.5 yrs left)· nominal 20-yr term from priority
C07K 16/2803C07K 2317/76C07K 2317/52C07K 2317/24A61K 2039/507A61K 2039/505A61K 39/39558C07K 16/2818A61P 35/00A61P 35/04C07K 2317/565
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.
Claims
exact text as granted — not AI-modified1 . A method for identifying an individual having a cancer who is a poor responder to treatment with an agent that neutralizes the inhibitory activity of human PD-1, the method comprising: a) determining levels of NKG2A expression on NK and/or CD8 T cells and/or numbers of NKG2A-expressing NK and/or CD8 T cells in an individual who has been treated with an agent that neutralizes the inhibitory activity of human PD-1; and b) upon a determination that the individual has increased levels of NKG2A expression on NK and/or CD8 T cells and/or increased numbers of NKG2A-expressing NK and/or CD8 T cells, identifying the individual as a poor responder to treatment with an agent that neutralizes the inhibitory activity of human PD-1.
Join the waitlist — get patent alerts
Track US2021122821A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.